This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rivera, E. Articles by Hortobagyi, G. N. Search for Related Content PubMed PubMed Citation Articles by Rivera, E. Articles by Hortobagyi, G. N.

Pilot Study Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of the Combination of Exemestane and Tamoxifen

¹ Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, and ² Pharmacia Corporation, Peapack, New Jersey

Purpose: We conducted a pilot study assessing the effects of the selective estrogen receptor modulator, tamoxifen, on the pharmacokinetics, pharmacodynamics, and safety of the steroidal, irreversible aromatase inhibitor (AI), exemestane, when the two were coadministered in postmenopausal women with metastatic breast cancer.

Experimental Design: Patients with documented or unknown hormone receptor sensitivity were eligible. Patients received oral exemestane at 25-mg once daily. Starting day 15, oral tamoxifen at 20-mg once daily, was added. We measured plasma concentrations of exemestane, estrone, estrone sulfate, and estradiol after 14 days of exemestane monotherapy and after 4 weeks of combination therapy. The incidence and severity of adverse events were assessed by physical examination and patient reporting.

Results: We treated 18 patients. All had received prior chemotherapy and/or hormonal therapy, eight and six, respectively, with single-agent selective estrogen receptor modulators or irreversible aromatase inhibitors; no hormonal therapy was given within 30 days of study entry. Plasma exemestane concentrations and estrone, estrone sulfate, and estradiol suppression were unchanged after 4 weeks of tamoxifen coadministration. All drug-related adverse events were grades 1 or 2; none was unexpected. Although not a formal study end point, antitumor activity was noted, with two partial responses and four cases of stable disease among 17 evaluable patients after a 9-month median follow-up (range, 2.5–19 months).

Conclusions: This pilot study provides evidence that coadministration of tamoxifen does not affect exemestane pharmacokinetics or pharmacodynamics and that the combination is well-tolerated and active. Further clinical investigation is warranted.

This article has been cited by other articles:

				P. R. Hutson, R. R. Love, T. C. Havighurst, E. Rogers, and J. F. Cleary Effect of Exemestane on Tamoxifen Pharmacokinetics in Postmenopausal Women Treated for Breast Cancer Clin. Cancer Res., December 15, 2005; 11(24): 8722 - 8727. [Abstract] [Full Text] [PDF]

				L. Radvanyi, D. Singh-Sandhu, S. Gallichan, C. Lovitt, A. Pedyczak, G. Mallo, K. Gish, K. Kwok, W. Hanna, J. Zubovits, et al. The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer PNAS, August 2, 2005; 102(31): 11005 - 11010. [Abstract] [Full Text] [PDF]

				R. R. Love, P. R. Hutson, T. C. Havighurst, and J. F. Cleary Endocrine Effects of Tamoxifen Plus Exemestane in Postmenopausal Women with Breast Cancer Clin. Cancer Res., February 15, 2005; 11(4): 1500 - 1503. [Abstract] [Full Text] [PDF]